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Abstract 
Background: In Finland, organized national mammography screening program has shown 
a decrease in mortality from breast cancer since its introduction in late 1980s. The 
incidence and mortality rate is rapidly rising in countries where regular screening program 
is not available. However, it is still not clear how much the presence of symptoms in 
screening exams increases the risk of breast cancer. We proposed a study to assess the 
association of earlier symptoms findings with the occurrence of breast cancer. 
Method: A cross-sectional study was performed among women aged between 50 and 69 
years who had breast cancer screening during the period 2006-2010. A total of 1.2 million 
mammography screening was performed and symptoms (lump, retraction, scar, secretion 
and mole) were reported by women and radiographer at the time of screening visit. Six 
thousand, four hundred and forty-five women were diagnosed with breast cancer. Breast 
cancer risk was calculated for each symptom using the odds ratios (OR) at 95% confidence 
intervals (CI) with or without interaction effect in logistic regression model. Moreover, 
tumor characteristics were linked with self-reported as well as radiographer reported 
symptoms. 
Results: Women reporting of lump had an increased odds of breast cancer in both self-
reported (OR = 7.23, 95% CI = 6.45 to 8.11) as well as in radiographer findings (OR = 
6.74, 95% CI = 6.12 to 7.41). Similarly, retraction had 3-fold increased risk of breast cancer 
in self-reported and 2.14-fold increase in radiographer reported findings. Other symptoms 
 
 
showed little increase in odds of breast cancer. The three-way interaction of symptoms 
(lump, retraction and scar) and the breast cancer risk was found higher in both self-reported 
(OR = 12.25, 95% CI = 2.93 to 51.12) as well as in radiographer reported (OR = 11.4, 95% 
CI = 4.63 to 28.09) symptoms. A lower sensitivity and higher specificity was found in self-
reported and in radiographer reported symptoms. 
Conclusion: Our findings reinforce the importance of fully evaluating the symptoms as a 
predictor of breast cancer. This study may be relevant for a large number of countries 
(without mammography screening program) to develop clinical breast examination as an 
alternative option in population-based breast cancer control, however, the impact may vary 
with study settings and availability of screening and diagnostic services.  
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1. INTRODUCTION 
 
 
Globally, breast cancer comprises 23% of the 1.1 million newly diagnosed cancers every 
year (Parkin 2002). Breast cancer is the most common cause of death in women across the 
world, both in developed and developing countries (Ferlay 2010). In 2008, approximately 
1.4 million women were diagnosed with breast cancer worldwide with corresponding 
460000 deaths. In the same year, approximately 450,000 women were diagnosed with the 
disease in Europe with a corresponding 140,000 deaths. (GLOBOCAN 2008) The upward 
trend in incidence is seen in many European countries especially among women ≥50 years 
of age indicating mammography as a primary contributor of the trend (Ferlay 2010). 
Developed countries accounts for 55% of the global burden; whereas the incidence rate is 
rapidly rising in developing countries due to increase in the background risk and increasing 
life expectancy. Early detection of breast cancer through organized screening in unselected 
women with an average risk in target populations has been impressive in reducing the 
mortality from the disease. Moreover, awareness regarding the diagnosis of early signs and 
symptoms in symptomatic population with access to high-quality treatment service is 
another way of preventing the fatal outcome (WHO 2012). 
 
Organized screening services for breast cancer have shown a decrease in mortality in many 
European countries and few other developed nations. In 1980s and early 1990s, several 
randomized control trials especially in northern European countries showed the 
effectiveness of screening for breast cancer, especially in reducing mortality and early 
detection of disease. In Finland, organized screening program reduced the mortality from 
breast cancer by approximately 20-28% among invited (Sarkeala et al. 2008). The mortality 
study after introduction of mammography screening in Denmark found a statistically 
significant 25% reduction associated with screening invitations (Olsen et al. 2005). 
Mortality study during past 3 decades in Sweden found a highly significant reduction (p-
value <0.001) in breast cancer mortality among those women invited for screening (Yen et 
al. 2011). Breast cancer screening has also been challenged leading to diagnosis or 
unnecessary treatment (Olsen & Gøtzsche 2006).  
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Despite the age-standardized incidence for breast cancer is four times lower in low and 
middle income countries compared to high income countries (Igene 2002), the mortality to 
incidence ratio is markedly high reflecting the low survival of the cancer cases (Harford 
2011). Prospective trials and observational studies on Clinical Breast Examination (CBE) 
have shown effectives in detecting cancer among asymptomatic women (Yip et al. 2008).  
Though the evidence is not sufficient, existing data shows that careful and competent CBE 
showed promising result in averting the deaths and detecting the lesions at an early stage 
for effective use of interventions (Weiss 2003). Breast Health Global Initiative has focused 
on breast cancer awareness and strengthening communication tools as an alternative for 
reducing the burden of disease in LMICs (Yip et al. 2008). In Finland, breast cancer has 
been continuously diagnosed as the most frequent cancer among women since 1960s, an 
age-standardized incidence of 94.6 per 100000 women (Finnish Cancer Registry, 2012), 
and accounted for 16.1 % of all cancer deaths in women from 2006-2010 (Nordcan 2012).  
 
However, screening by mammography with appropriate management services for the 
women with the positive test has been a costly method of diagnosis and therefore, in spite 
of the lack of sufficient evidence in reducing mortality by CBE and BSE (Breast Self-
Examination), improved breast cancer outcome and survival though early detection of 
tumors remains a corner stone of breast cancer control. We assumed that there should be 
some kind of linkage between symptomatic findings at the time of screening with the 
occurrence of breast cancer. No study till date, has measured the association of earlier 
symptomatic findings and the occurrence of breast cancer among women screened through 
the organized screening program in Finland, and there are very few earlier reports from 
other programs. Radiographer performs clinical examination during the screening visit and 
also records symptoms reported by the screened. Some of the symptoms traits in this 
clinical examination may also be needed for the interpretation of images. In addition, the 
radiologist palpates findings at the recall visit. Describing symptoms in screen-detected 
breast tumors can provide clues to understand better the natural history of disease. Findings 
from the study could convey an important message for the clinicians (radiologists) about 
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symptoms of breast cancer and might help in making rational decision regarding the further 
investigation (recall or referral, if needed), which indeed improves the unnecessary 
diagnosis or reduce false positive cases. Moreover, for developing countries, where the 
facility for detecting cancer at an early stage is not possible, symptomatic findings can be 
used as an indication for early diagnosis of disease which could prevent the women from 
late stage presentation of disease. We proposed a study to measure the association between 
breast cancer symptoms, self-reported and/or radiographer reported and the occurrence of 
breast cancer. We also examined the clinical validity of the symptoms as well as the 
association between symptoms and tumor characteristics.  
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2. LITERATURE REVIEW 
 
 
2.1. Common breast problems 
 
Though the exact causes of breast cancer are unknown, the disease occurs when the 
malignant cells form a tissue in the breast and passes through various stages to cause the 
disease. Most commonly, when women feel symptoms of breast pain, secretion or breast 
lump she consults a physician. The possibility of having breast cancer varies with the age of 
women and the presenting breast complaints. Breast lump is the growth of tissue in the 
breast and described as a mass, swelling or thickness of breast. Most of the times breast 
lump results from noncancerous (benign) conditions however sometimes it is seen as a sign 
for breast cancer (MedlinePlus 2013). Breast pain more frequently occurs in pre-
menopausal women and hormonal factor is suggested as its etiology however in post-
menopausal women the etiology is unknown. Nipple discharge, usually occurs due to 
benign process, has been reported in 10 to 15 percent of women with benign breast disease 
and 2.5 to 3 percent of women with breast cancer. Patients with spontaneous or unilateral 
nipple discharge are usually referred for surgical evaluation. (Morrow 2000)In vast 
majority of the cases, retraction usually occurs as a result of nipple ducts malformation and 
sometimes due to the inflammation in the breast and breast diseases such as breast 
hypertrophy. Retraction may present in one or both sides of the breast in 2 to 10 percent of 
the women (BreastAugmentation 2013). A scar is a star-shaped breast mass most often 
benign or may be precancerous or contain a mixture of tissue, including hyperplasia, atypia 
or cancer or sometimes it causes breast pain. If the scar is rather large it may appear on the 
screening mammogram (Breastcancer 2011).  
 
 
2.2. Screening techniques 
 
Mammography is a clinical tool to detect breast cancer either through screening 
asymptomatic women or by examining symptomatic patients. High quality mammograms, a 
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primary screening tool in developed countries, are proven to detect cancer at an early stage 
with minimal exposure of the women to radiation (IARC 2002). However, because of the 
high cost it is rather a cost-ineffective choice for developing countries. Women with 
cancerous tumors detected by mammography screening have better distant disease-free 
survival and have histological and biological features with relatively low malignant 
potential compared with tumors detected between mammography screening rounds or 
tumors found outside of screening (Joensuu et al. 2004). Therefore, screening enables the 
detection of breast cancers at an earlier stage of disease. It is now well documented that 
screen-detected cancers are generally smaller, of lower grade and less likely to have 
axillary lymph node involvement (Weaver et al. 2006).  
 
Clinical Breast Examination by health care provider includes a visual examination and 
carefully feeling the entire breast. CBE is an important tool of screening for women who do 
not get access to mammography screening. Though the effectiveness in reducing mortality 
is not known (Sankaranarayanan et al. 2011), CBE can serve as an opportunity for the 
health care providers to raise awareness about various aspect of breast cancer (Smith et al. 
2003)improve access to care. Evidence on the additional benefit of clinical breast 
examination to the mammography screening rather than mammography alone is insufficient 
(U.S. Preventive Services Task Force 2009). Screening by CBE in community based study 
showed however that cancer cases are frequently missed by CBE which ultimately prove to 
be lethal (Fenton et al. 2005). More importantly, lower sensitivity of CBE was found by 
several community-based studies in United States (Fenton et al. 2005; Bobo et al. 1999;  
Oestreicher et al. 2002).  
 
Breast Self-Examination (BSE) is a technique that women can monitor changes in her 
breast which may contribute to early detection of the cancer followed by further 
investigation (Erskine & Crowe 1998). BSE necessitates regular inspection, with a diary. 
Breast Self-Examination study in a cohort of 28,785 women in Finland found lower breast 
cancer mortality (RR of 0.75) (Gastrin et al. 1994). Though there is only little evidence on 
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mortality reduction by BSE, there is always a chance or option of detecting the palpable 
mass at an early stage of the disease (Sauter & Daly 2010; Foster et al. 1978). 
 
 
2.3. Symptoms of breast cancer 
 
Clinical breast examination was done in a population based study of 2,879 self-selected 
women with breast complaints. The aim was to identify the risk of breast cancer among 
women in all ages. Breast lump was most common in patients who were above 40 years of 
age and pain was most common among patients below 40 years of age (p-value less than 
0.01). Eleven percent of the women had histological confirmed breast cancer whereas 16% 
of the patients who had breast lump found to have breast cancer. Similarly, breast cancer 
was found in 12% of the patients with nipple discharge and 3.2% of the patient with breast 
pain. Cancer detection rate was significantly higher in older age group (31.2% in above 55 
years of age) and less than 1% in women below 40 years of age (p-value less than 0.01). 
Patient above 55 years with complaints of lump were three times higher risk of breast 
cancer (95% CI= 1.5-6.3). No increased relative risk was found in patients below 40 years 
of age (Lumachi et al. 2002).  
 
A cross-sectional survey was performed in a stratified sample of general population in 
Denmark. A total of 13,777 women aged 20 years and above were randomly selected to 
investigate the possible association between socio-economic and demographic determinants 
and reporting of cancer alarm symptoms within the preceding 12 months. One or more 
cancer alarm symptoms were reported in 2098 (15.7%) participants with the mean age of 
49.7 years. Four hundred and eleven participants (3.3%) reported lump in the breast, 940 
participants (6.5%) reported cough for more than 6 weeks, 307 participants reported blood 
seen in the urine, and 713 participants (5.8%) reported blood seen in the stool. 
Socioeconomic and demographic determinants were found to be associated with cancer 
alarming symptoms (Svendsen et al. 2012).  
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An observation study conducted among post-menopausal women between 1996 and 2001 
who had either diagnostic (13524 women) or screening examination (110,323 women) and 
examined the association between self-reported symptoms and the risk of breast cancer. 
Symptoms were reported by 32% of the women who had a diagnostic examination, 
compared to 5% of women who had the screening examination. Women who reported 
symptoms were at higher risk of developing breast cancer compared to asymptomatic 
women, 13 versus 6 women per 1000 population per year, respectively. A reported lump, 
after adjusting for confounders, was significantly associated with increased risk of breast 
cancer in both diagnostic (OR= 2.8, 95% CI= 2.3-3.4) and screening examination (OR= 
3.6, 95% CI= 2.6-5.0). Nipple discharge showed a small increase in the risk of breast 
cancer in the diagnostic and screening examination (OR= 1.5 and 1.8 respectively) whereas 
pain and other symptoms showed no increased risk of breast cancer. Lump was the most 
predictive symptom of breast cancer (136 per 1000 women per year in diagnostic exam and 
36 per 1000 women per year in screening exam) among women with prior examination 
compared to asymptomatic women (15 per 1000 women per year in diagnostic exam and 2 
per 1000 women in screening examination) who had prior examination (Aiello et al. 2004).  
 
A study in USA used mammography registries as the data source to evaluate the 
performance of diagnostic mammography among women with or without symptoms of 
breast cancer. Of the 41,427 women analyzed 1,598 were diagnosed with breast cancer and 
carcinoma in-situ. Lump was diagnosed in 72.2% women with a diagnosed breast cancer 
while only 47.4% of the women reported that lump was not diagnosed with breast cancer. 
Similarly, the reporting percentage as having any symptoms were higher in women with 
breast cancer than in women without breast cancer, 83.6% versus 75.6% respectively. 
Women with breast lump and lower breast density showed higher sensitivity (p-
value=0.039 and 0.016 respectively) but not significant with age (p-value=0.099) however 
specificity was lower in women with increasing breast density and self-reported lump 
(Barlow et al. 2002). A case-control study in Italy was performed to evaluate the risk of 
breast cancer in symptomatic women compared to healthy and symptomatic non-screened 
women without breast cancer. Multivariate analysis using logistic regression model 
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adjusted for age showed covariates; no pregnancy, first birth greater than 30 years of age, 
use of estrogen replacement therapy (ERT) were significantly correlated (p-value <0.01) 
with breast cancer onset with relative risk of 5.25, 2.47 and 5.56 respectively (Lumachi et 
al. 2002).  
 
A cross-sectional study in Australia was conducted among women age 40 years and above 
between 1
st
 January 1994 and 31
st
 December 1994. The study included 106826 women who 
first visited for breast examination by mammography through organized screening 
program. 9.7% of the women were symptomatic where 2.6% reported a lump or blood 
stained or watery nipple discharge (referred as significant symptoms) and 7.1% reported 
breast pain or tenderness (referred as other symptoms). The sensitivity was 80.8% in 
women with significant symptoms and 60% in women who had other symptoms. The 
specificity was comparatively higher in women with other symptoms than with significant 
symptoms, 95.4% versus 73.7% respectively (Kavanagh et al. 2000). A study in USA 
analyzed the mammogram data of 59321 women aged 25 years and above in 2 years’ time, 
from January 1996 to December 1997. Seventy-two percent of the women reported some 
kind of symptoms in the breast. The most frequent symptom reported by women was breast 
lump (52.3%) however the percentage decreased with age from 63.5% in women aged 25-
44 years to 36.5% in women aged 65 years or greater. Nipple discharge was reported by 
7.6% of the women (Geller et al. 2002). A retrospective cohort study on breast symptoms in 
UK was conducted among 2,400 women aged 40 to 69 years, who come for health 
maintenance organization in 10-year period. Sixteen percent of the women were presented 
with breast symptoms during 10 years period. The screening rate was lower in women 
before they were presented with symptoms but increased afterwards. Twenty-seven of the 
population was referred for the further investigation and cancer was detected in 6.2% of the 
patients (Barton & Elmore 1999). A retrospective analysis of 2,561 symptomatic women 
was done to see the correlation between breast complaints and risk of developing breast 
cancer in Italy. Breast pain was most common in women aged 40 years or below whereas 
breast lump was common in women greater than 55 years of age. Cancer was developed in 
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10.6% of the women. There was no correlation between breast lumps or nipple discharge 
and breast cancer (Lumachi et al. 2002).   
 
A correlation analysis of breast complaints with age and breast cancer was done in 2,000 
patients who made complaints of breast symptoms for the first time. Initially, 50% of the 
patients complained about breast lump, 6% complained breast pain, 4% complained nipple 
discharge and 8% complained of other symptoms. One-hundred and forty-seven cancer 
cases were identified among 1,889 women from whom follow-up information was 
available. Breast cancer was diagnosed in 16.1% of the patients aged 50 years or older 
while only 4% of the patients’ age between 30 years and below 50 years had cancer. Most 
of the patients (92%) referred to breast surgery did not have malignancy (Seltzer 1992). A 
study conducted to assess the relevance of reported symptoms in breast cancer screening 
program in UK identified 1,394 women as having significant symptoms between 1991 and 
1996. Majority of the women complained of a lump (54%), 18% complained pain and 6% 
complained nipple discharge. Two hundred and sixty-two women were recalled because of 
the mammographic abnormality whereas 498 women who had symptoms and benign 
mammograms were recalled. Of these, 7 were diagnosed with breast cancer who previously 
complained of breast lump (Williams et al. 2002).  
 
 
2.4. Screen detected versus symptomatic breast cancers outside screening 
 
A comparative study among 767 patients (103 cases of screening detected and 664 
symptomatic cases detected outside screening) on screen detected and symptomatic breast 
cancer patient was done in two affiliated high volume institution in Singapore. Eighty-nine 
percentage of the symptomatic group was presented with palpable lump compared to 40% 
in the screening group. In-situ carcinoma was found higher in the screening group 
compared to symptomatic, 31% and 14.3% respectively.  The median size of invasive 
cancer was significantly lower (p-value ≤0.001) in screening group (18mm) than that in the 
symptomatic group (23mm). Invasive cancer was detected in 23.9% of the screen detected  
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women with tumor size of 10 mm or less compared to 14.4% in the symptomatic group (p-
value=0.06). Similarly, screening detected cancer had less frequent lymph node 
involvement (35.2 versus 45%), lower stage(95 versus 83.2 for stage 0-2, p=0.005), 
histological grade 1 and 2 (70.9 versus 60%) and lower incidence of lympho-vascular 
invasion (14.1 versus 36.9%) compared to symptomatic cancers. Fourteen patients had 
disease recurrence, of whom 28.6% had loco-regional recurrence while 71.4% had distance 
sites (Chuwa et al. 2009). 
 
A nested case control study was performed in Spain among 291 women diagnosed with 
breast cancer and who had undergone surgical resection in a hospital between 1996 and 
2007. The mean size of tumor was significantly smaller (1.62±0.14 versus 2.68±0.15, p-
value <0.001) in screen detected women than in symptomatic women. Similarly, screened 
women had a lower rate of axillary lymph node metastases (22.3 versus 48.9%, p-value 
<0.001) and a higher percentage of in-situ carcinoma (11.4 versus 1.5%, p-value <0.001) 
(Redondo et al. 2012).Another comparative study in UK by Gibbs (1985) found 31% of the 
screened patients with in-situ carcinoma compared to 7% in the unscreened population. 
Likewise, 26% of the screened patients had cancer less than 2 cm compared with 52% in 
the unscreened group. 
 
Similar study in West Midlands, UK compared invasive breast cancer characteristics in 
19411 screen-detected and symptomatic women between 1988 and 2004. The mean size of 
the tumor was 16.5 mm in screened women compared to 26.1 mm in symptomatic women 
(P< 0.0001). Screened women had a lower rate of lymph node metastases (27% versus 
48.1%, P< 0.001) and lower percentage of grade-3 carcinoma (20.7% versus 44.7%, 
P<0.001) compared to symptomatic women (Allgood et al. 2011). Similar findings were 
found by Bucchi et al. (2005) while studying symptomatic and clinical breast cancer during 
the period between 1988 and 1999. Screening cases were more favorable to smaller tumor 
size (73% versus 48% in tumor ≤ 17mm, p-value= 0.000) and lower lymph node 
involvement (23% versus 40%) than clinical breast cancers. The proportion of node 
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positive cases was positively associated with tumor size (p-value= 0.000) in both screen-
detected and clinical breast cancer.  
 
Rajakariar and Walker (1995) studied 107 invasive carcinomas detected by Leicestershire 
Breast Screening Service (UK) during the period 1990-92. Mammographic screening group 
were in higher proportion in lower grade class (grade 1- 30% versus 15%, grade 3- 9% 
versus 37%) and lower frequency of lymph node metastases (6.5% compared with 55%) 
compared to symptomatic group. Thirty-six percent of the screened detected carcinomas 
were 10 mm or less in diameter compared to 1.4% in symptomatic group. Another study in 
UK studied 1379 women diagnosed with invasive breast cancer found that screening group 
had smaller breast cancer size compared to the symptomatic group (85% and 59% 
respectively for tumor size ≤ 2 cm, p-value <0.0001). Tumors detected though screening 
were of lower histological grade (34 versus 23% for grade 1, p-value <0.0001) and less 
likely to have lymph node involvement (25 versus 40%, p-value <0.0001) compared to the 
tumors detected in symptomatic group (Dawson et al. 2009). A comparative study in Korea 
showed that screen-detected cancers were associated with smaller tumor size, less lymph 
node involvement, earlier stage, and reduced mortality compared with symptomatic breast 
cancer (p-value < 0.001) (Kim et al. 2012). 
 
In 2004, a study by Joensuu and colleagues found that tumors of 10 mm or smaller in 
diameter were higher among those detected by screening compared to the tumors detected 
outside of screening (38% versus 14%), and were less commonly associated with axillary 
lymph nodes metastases (21 versus 35%, p-value <0.01). Similarly, higher grade (Grade 3) 
tumors were less common in screening detected breast cancers compared to outside of 
screening (13 versus 22%). A comparative study among symptomatic and asymptomatic 
breast cancers in Verona, Italy (with no organized public screening program) found that 
symptomatic breast cancer cases were detected more in higher grading class and with larger 
tumor size than asymptomatic cancers (grade 1- 9.6 versus 21.2%, grade 3- 33.7 versus 9.6; 
T1- 57.4 versus 82.6%, T2-39.4 versus 16.6%, T3- 3.2 versus 0.8%) (Molino et al. 2000). 
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2.5. Mass screening versus out-patient clinics 
 
A research group in Tokyo, Japan studied 2,170 breast cancer patients (728 patients 
detected by mass screening and 1450 patients found in out-patient clinics) from clinical and 
pathologic records of Japan Mammary Cancer Society found that earlier stage were 
significantly more common in patient detected by mass screening (stage I- 40.9% versus 
28.7% and stage III- 9.3% versus 14.6%) as well as tumor size was significantly smaller 
among mass screening group than in out-patient clinics group (Tis, T0 plus T1- 38.7% 
versus 29.7% and T4- 3.6% versus 7.7%). Subjective symptoms (mainly breast lumps, 
nipple discharge and pain etc.) was present in 66.5% of the patient detected by mass 
screening compared to 98.2% of the patients in outpatient clinics (p-value <0.01). Breast 
Self-Examination (BSE) and fortuitous discovery of tumor masses was more common in 
patient detected by mass screening (p-value <0.01) (Ota et al. 1989). 
 
 
2.6. Recall rate, screening mammography, sensitivity and PPV 
 
A study conducted in Finland assessed the quality of mammography screening program 
using data of 10 screening centers from 1991-2000 among 100,000 women aged 50-64 
years. The cancer detection rate for first time screening and subsequent screening women 
was 0.44% and 0.36% respectively whereas PPV of mammography was 9.6% and 15.8% 
respectively. Breast cancer by surgical biopsy was detected in 50% of the women who had 
first time screening and 70% in subsequent screening. Among the centers the recall rate in 
the subsequent screening varied 1% to 3.6% and cancer detection rate varied from 0.30% to 
0.43%. The benign to malignant ratio in first and subsequent screening was 1:1 (range 0.5-
1.8:1) and 0.4:1 (range 0.3-0.8:1) (Sarkeala et al. 2004).  
 
Another study on cancer detection and recall rate by Harvey and colleagues (2003) 25,369 
women in USA found overall recall rate of 14.2%. The cancer detection rate in double 
interpretation mammography was 5.6 per 1000 and 5.3 per 1000 in screening mammograms 
without double interpretation, a relative increase detection of 6.3% as a result of second 
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reviewer, while sensitivity increased from 74.4% to 79.4.Higher sensitivity was found in a 
cross-sectional study in northern California by Kerlikewoske and colleagues (1996). 
Sensitivity was 98.4% in women aged 50 years and older with primarily fatty breast 
whereas 81.4% sensitivity was found in younger women aged below 50 years. Similarly, 
for dense breast sensitivity was 83.7% for older women and 85.4% for younger women.  
 
Community based studies in United States found rather low sensitivity of CBE. Fenton et 
al. (2005) studied asymptomatic women diagnosed or died of breast cancers in five states of 
USA found sensitivity of 21.6% (CI 18.1% to 25.6%). Another national level study using 
CBEs data between 1995 and 1998 found overall sensitivity, specificity and PPV of 58.8%, 
93.4% and 4.3% respectively. However, sensitivity fell down when analyzing the data 
among asymptomatic women (sensitivity 36.1% and specificity 96.2%) (Bobo et al. 1999). 
A sensitivity study of CBE conducted between 1988 and 1994 in USA found a increase in 
sensitivity with increase in tumor size (17% for tumors size ≤5 mm and 58% for tumors 
size ≥21 mm, adjusted p for trend < 0.001) (Oestreicher et al. 2002). A preliminary findings 
of cluster randomized control trail on breast cancer screening by CBE in India showed 
moderate sensitivity of 51.7% (CI= 38.2% to 65.0%) and high specificity of 94.3% (CI= 
94.1% to 94.5%) but low PPV (1%) and high false positive value (5.7%) 
(Sankaranarayanan et al. 2011). 
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3. STUDY AIMS 
 
 
The main aim of the study was to assess the association of symptoms findings with the 
occurrence of breast cancer among screen detected women under the organized national 
breast cancer screening program of Finland. 
The specific aims were: 
o To compare symptoms of breast cancer among women by age and year of 
screening.  
o To find out the test positivity and referral rate among women with and without 
symptoms.  
o To analyze the clinical validity of the symptoms among women with and without 
symptoms.  
o To identify the difference in tumors characteristics among women, with and without 
symptoms, detected as having breast cancer.  
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4. MATERIALS AND METHODS 
 
 
This study is based on the breast cancer screening data provided by Finnish Cancer 
Registry collected between the year 2006 and 2010. 
 
 
4.1. The Finnish Cancer Registry as a source of data 
 
Finnish cancer registry receives the information on breast cancer screening program from 
the screening centers involved in the program. Registration is based on the law and decree 
on personal data in the health-care system, 1989; and the respective recommendations 
published by the National Research and Development Centre for Welfare and Health 
(Finnish Cancer Registry 2013).The mass screening registry, a section of Finnish Cancer 
Registry, maintains the national database of the screening and evaluates the impact of 
screening on mortality as well as the quality of the program. The unique personal 
identification number of each individuals helps to eliminate duplicate records.  
 
 
4.2. Selection of the study population and study variables 
 
National breast cancer screening age group (50-69) comprises 26.76% of total female 
population of Finland. The municipality organizes the screening program biannually and 
free of charge to all women aged between 50 and 69 years at especially organized breast 
cancer screening units. Women are recalled for further assessment by additional 
mammography, ultrasound or other screening techniques if the first mammogram is 
inconclusive. If the results after the further assessment are still positive, women are referred 
to surgery and, biopsy with open surgery is performed as the first step. Information about 
screening episode up to primary surgical treatment is gathered from the screening centers 
based on the information provided in the screening process. For the current study, 
information about the women aged 50-69 years who had breast cancer screening between 
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the year 2006 and 2010 were chosen. The study is totally based on the information recorded 
in the mammography screening form filled 
(http://www.cancer.fi/syoparekisteri/joukkotarkastusrekisteri/) for every woman who was 
screened during that period of time. Altogether 1,454,143 invitations were made during the 
period between 2006 and 2010, out of which 1,241,486 screening visits were made with a 
total attendants of 85.4%. 4,429 visits were excluded from our study because of the age 
limitations. Furthermore, 38,647 visits were excluded because of the incomplete 
information on either clinical examination of breast or self-reported symptoms. The final 
data set contains 1,198,410 screening visits which includes 331,589 women from all over 
Finland.  
 
Considering the purpose of the study, five variables were selected to see the association of 
the symptoms with the breast cancer outcome. Information about the symptoms was 
reported by the women as well as by the radiographer. Symptoms (lump, retraction, scar, 
secretion and mole) as well as age of the screened women and year of screening were 
selected as covariates whereas breast cancer is considered as the outcome (dependent) 
variable. Moreover, the tumor characteristics (tumors size and grades) were linked to the 
covariates, especially the symptoms variables.  
 
 
4.3. Ethical considerations 
 
Information on the breast cancer symptoms and cancer outcome, as well as population 
number and demographic variables were based on tabular statistical data only. Hence, no 
approval from the ethical committee was required. 
 
 
4.4. Measurement of variables 
 
Information on breast cancer symptoms and cancer outcomes were assessed by using the 
mammography screening form used by breast cancer screening clinics in Finland. At the 
24 
 
time women attends for screening, they complete a questionnaire or provide information by 
request from the radiographer giving details of the symptoms history in the past two months 
as well as the demographic information. The breast cancer symptoms were further assessed 
by doing inspection and palpation of the breasts by the radiographer. Information of 
symptoms was then recorded in the same mammography screening form previously filled 
by the women. Women who had symptoms in either or both sides of the breast were 
considered as symptoms, may be the self-reported or radiographer reported symptom. 
 
Breast symptoms were dichotomized as the value 1 indicates ‘symptom’ and 0 indicates ‘no 
symptom’. The outcome of breast cancer were categorized as; in-situ and invasive as 
‘malignant’, and benign as ‘no malignant’.  Age of the screened women were categorized 
into 4 groups as ’50-54years’, ’55-59 years’, ’60-64 years’ and ’65-69’ years respectively. 
To do the trend analysis of symptoms with age, age-groups were made as continuous 
variables as age-group 50-54 years indicate ‘0’, 55-59 years indicate ‘1’, 60-64 years 
indicate ‘2’ and 65-69 years indicate ‘3’. Similarly, to do trend analysis of symptoms with 
year, year categories were made as continuous variables as year 2006 indicate ‘0’, 2007 
indicate ‘1’, 2007 indicate ‘2’, 2008 indicate ‘3’, 2009 indicate ‘4’ and 2010 indicate ‘5’. In 
classifying histological confirmed tumors four categories of tumor size were made; ‘less 
than 10mm’, ‘10-19mm’, ‘20-49mm’ and ‘50-150mm’. Moreover, tumors were classified 
following the PTNM classification of tumors published by International Union Against 
Cancer (UICC) in 2002.  
 
 
4.5. Statistical analysis 
 
Statistical analysis was carried out using Stata version11.0. Two-sided p<0.05 was 
considered as to be statistically significant. A logistic regression model was used to 
calculate crude and adjusted odds ratios (OR) with 95% confidence interval (CI) using 
Wald statistics for individual terms. The univariate logistic regression model was used to 
estimate the odds ratios with 95% CI for association of symptoms findings with the 
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occurrence of breast cancer. For calculating the interaction effects and trend analysis 
likelihood ratio statistics was used. Symptoms were further stratified by age of the screened 
women and year of screening, and estimated the odds ratios with 95% CI on the occurrence 
of breast cancer. The association of symptoms with the recall of women who had 
mammography was estimated using univariate logistic regression model calculating the 
odds ratios with 95% CI. Similarly, women with symptoms status and referral cases for 
further assessment were put into a logistic regression model to estimate the odds ratios with 
95% CI.  
 
A two-way interaction effect (individual and combined effect) between the self-reported 
and radiographer reported symptoms, and the breast cancer risk was estimated using the 
odds ratios with 95% CI. Moreover, a three-way interaction effect (individual and 
combined effect) with all possible combination of the symptoms, however separately for 
self-reported and radiographer symptoms, were used to estimate the breast cancer risk 
calculating the odds ratios and 95% CI. Association of breast cancer symptoms and tumor 
characteristics were assessed by calculating odds ratios with 95% CI.  
 
Sensitivity is the number of women with screen detected malignant (invasive) cancers and 
who had symptoms (true positives) divided by the total number of malignant (invasive) 
cancer cases (true positive and false negative). Specificity is the number of women without 
symptoms and no malignant cancer cases (true negatives) divided by the total number of no 
cancer cases (true negative and false positive). These measures of sensitivity and specificity 
are the direct measures of the clinical validity of symptoms and are expressed in percentage 
(%). Confidence interval for sensitivity and specificity was produced with the Wilson score 
method (Newcombe 1998). Positive predictive value is the likelihood of being detected as 
malignant cancer among those who had symptoms, when referred for histological 
confirmation (true positive cases divided by the sum of true positive and false positive 
cases). Confidence interval for positive predictive value was calculated using the method 
described by Simel and colleagues (1991). Correlation coefficient was calculated to see the 
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extent to which self-reported and radiographer reported symptoms were related. The 
correlation coefficient of lump, retraction and scar was 0.632, 0.382 and 0.788 respectively.  
 
 
4.6. Clinical decision tree 
 
The figure below shows the breast cancer screening process of the national breast cancer 
screening program in Finland. The result of the study is based on the information collected 
in the process of breast cancer screening and diagnosis.  
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Breast symptoms 
 
 
 
 
 
 
1. Symptoms 
 
2. Mammography  
 (Home) (Home) 
   
         
        3.   Recall   
   
      
 
 
        4. Referral 
 
 
        5. PAD behavior  
 
Figure 1: Flow chart of Breast cancer screening and diagnosis process. 
 
 
Inspection palpation Self-reported 
Yes  No  Yes   No 
Yes  No  No Yes 
Yes Yes  No   No
 
Retraction Scar Secretion Mole Lump  
Presence  Absence  
Positive  Negative  Positive  Negative  
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5. RESULTS 
 
 
Table 1: Characteristics of breast cancer reported, by year of screening and age of 
screened women 
 
 Breast cancer 
 
 
Cases (%) No cases (%) Total (%) 
Screeningvisits 6545(0.55) 1191865(99.5) 1198410(100) 
Year of  
screening 2006 936(0.49) 191956(99.5) 192892(16.1) 
 
2007 1195(0.51) 234109(99.5) 235304(19.6) 
 
2008 1378(0.58) 236011(99.4) 237389(19.8) 
 
2009 1511(0.56) 266636(99.4) 268147(22.4) 
 
2010 1525(0.58) 263153(99.4) 264678(22.1) 
Age of 
women 50 - 54  1982(0.42) 467612(99.6) 469594(39.2) 
 
55 - 59 1713(0.50) 337922(99.5) 339635(28.3) 
 
60 - 64 2044(0.67) 304183(99.3) 306227(25.6) 
 
65 - 69 806(0.97) 82148(99.0) 82954(6.9) 
Recall yes 6545(21.5) 23847(78.5) 30392(2.5) 
 
no 0(0.00) 1167688(100) 1167688(100) 
Referral yes 6540(80.8) 1553(19.2) 8093(0.75) 
 
no 4(≈0.00) 1073458(≈100) 1073462(100) 
 
 
Table 1 shows the Breast Cancer incidence by screening year and age of screened women. 
The final data set contains 1,198,410 screening visits. Breast cancer was diagnosed in 6,545 
(0.55%) women. In 2006, 192,892 screening visits were carried, out of which 936 (0.49%) 
were found to have cancer. In 2007, cancer cases went to 1,195 among those 235,304 
women who were screened. In 2010, of the 264,678 women screened 1,525 women were 
detected with breast cancer. Similarly, breast cancer cases were high (2,044 cases) in 
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women age between 60 and 64 years and low (806 cases) in women age between 65 and 69 
years whereas more screening visits (469,594 visits) were made by women of aged 50-54 
years  and less screening visits were made by older women (82,954 visits in age group 65-
69 years). Of the 30,392 (2.54%) women recalled 6,545 had cancer and among the 8,093 
women who were referred 6,540 were found to have cancer.  
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Table 2: Breast cancer risk among women reported as having either self-reported (sf) or radiographer reported (ip) 
symptoms 
   
Breastcancer 
  
  
Cases (%) No cases (%) Total (%) 
Odds 
ratio 95% CI 
Self-reported 
     Lump Yes 320(3.67) 8410(96.3) 8730(0.73) 7.23 6.45-8.11 
 
No 6225(0.52) 1183376(99.5) 1189601(99.3) 1 
Retraction Yes 67(1.65) 3982(99.35) 4049(0.34) 3.08 2.42-3.93 
 
No 6478(0.54) 1187803(99.5) 1194281(99.7) 1 
Scar Yes 697(0.7) 98698(99.30) 99395(8.29) 1.32 1.22-1.43 
 
No 5848(0.53) 1093089(99.5) 1098937(91.7) 1 
Secretion Yes 43(1.08) 3922(98.3) 3965(0.33) 2.00 1.48-2.71 
 
No 6502(0.54) 1187862(93.5) 1194364(99.7) 1 
Radiographer 
Reported 
   Lump Yes 465(3.36) 13377(96.6) 13842(1.16) 6.74 6.12-7.41 
 
No 6080(0.51) 1178406(99.5) 1184486(98.8) 1 
Retraction Yes 232(1.14) 20100(98.9) 20332(1.70) 2.14 1.88-2.44 
 
No 6313(0.54) 1171683(99.5) 1177996(98.3) 1 
Scar Yes 920(0.69) 133007(99.3) 133927(11.2) 1.30 1.21-1.39 
 
No 5625(0.53) 1058776(99.5) 1064401(88.8) 1 
Mole Yes 963(0.64) 150066(99.4) 151029(12.6) 1.19 1.11-1.28 
 
No 5582(0.53) 1041717(99.5) 1047299(87.4) 1 
*CI= confidence interval 
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Women who reported as having symptoms, lump was reported in 8,730 screening visits. Of 
which, cancer was found in 320 women (3.67%). Whereas, 67 (1.65%) of 4,049 screening 
visits were retraction was reported, found to have cancer. Similarly, scar was reported in 
99,395 screening visits. Out of which, cancer was found in 697 (0.7%) women. Secretion 
was reported in 3,965screening visits. Out of which 43 (1.08%) were found to have cancer. 
Women who reported lump were 7.23 times higher risk of developing breast cancer 
compared to women who did not report as having lump. Women reported retraction were 
3.08 times higher risk of developing breast cancer compared to those who reported as 
having secretion and scar, higher risk of 2 times and 1.3 times respectively.  
 
In inspection and palpation, lump was reported in 13,842 screening visits in which 465 
(3.36%) women were found to have breast cancer. Retraction was reported in 20,332 
women, out of which 232 (1.14%) were detected with cancer. Similarly, scar was reported 
in 133,927 screening visits and mole in 151,029, out of which cancer was detected in 920 
and 963 women respectively. The risk of developing breast cancer was significantly higher 
(odds ratio= 6.54) in women reported as having lump. Women detected as having 
retractions were 2.14 times at higher risk of developing breast cancer compared to those 
who had scar or mole, 1.3 and 1.9 times.  
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Table3:  Odds ratios (ORs) and confidence intervals (CIs) for joint exposure to self-
reported or radiographer reported symptoms  
 
Symptoms Odds ratio 95% CI 
Sf-lump # ip-lump 
  0 0 1 
 0 1 5.28 4.54 - 6.13 
1 0  4.10 2.95 - 5.71 
1 1 8.25 7.31 - 9.32 
Sf-retraction # ip-retraction 
  0 0 1 
 0 1 1.96 1.69 - 2.28 
1 0 3.81 2.10 – 6.93 
1 1 3.02 2.32 - 3.94 
Sf-scar # ip-scar 
  0 0 1 
 0 1 1.28 1.14 - 1.45 
1 0 1.60 1.21 - 2.10 
1 1 1.32 1.21 - 1.43 
*sf= self-reported; ip= inspection palpation (radiographer reported); CI= confidence 
interval; 
0= absence of symptom; 1= presence of symptom 
 
Table 3 shows the breast cancer risk among women calculated using the interaction effect 
on self-reported and radiographer reported symptoms. The combined risk of developing 
breast cancer was 8.25 times higher in women where lump was reported by both women 
and radiographer compared to those who had no lump. The risk of self-reported lump was 
5.28 times higher and for radiographer reported lump the risk was 4.10 times higher. 
Women with self-reported retraction were 3.81 times higher risk of developing cancer 
compared to the radiographer reported retraction where the risk was 1.96 times higher. 
Women who had self-reported and radiographer reported retraction the risk was 3.02 times 
higher whereas in case of scar, the combined risk of developing breast cancer was little 
higher (1.32 times) than those who had no scar.  
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Table 4: Odds ratios (OR) with confidence intervals (CI) for exposure to self-reported or radiographer reported 
symptoms reported by year of screening  
   
Breast cancer risk 
 Symptoms/Year 
Self-reported 
Radiographer 
reported 
Odds 
ratio 95% CI 
P-value for  
homogeneity 
Lump|total 8730 13842 
   lump|2006 1319 2304 8.54 6.19-11.8 
 lump|2007 1705 2680 6.70 4.90-9.12 
 lump|2008 1715 2626 9.00 6.94-11.7 
 lump|2009 1920 3007 8.94 7.00-11.4 
 lump|2010 2070 3225 7.93 6.19-10.1 0.10 
     Retraction|total 4049 20332 
  retraction|2006 516 3364 2.33 0.96-5.64 
 retraction|2007 705 3757 3.37 1.80-6.32 
 retraction|2008 947 4144 1.99 1.03-3.86 
 retraction|2009 959 4425 3.26 1.95-5.45 
 retraction|2010 921 4642 3.80 2.35-6.17 0.84 
      Scar|total 99395 133927 
   scar|2006 15516 20950 1.40 1.13-1.74 
 scar|2007 18845 26281 1.03 0.83-1.29 
 sacr|2008 19509 26432 1.41 1.19-1.69 
 scar|2009 23554 30366 1.34 1.14-1.58 
 scar|2010 21964 29894 1.35 1.44-1.59 0.81 
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Secretion|total 3965 
secretion|2006 726 
 
2.29 1.14-4.62 
 secretion|2007 879 
 
1.35 0.60-3.01 
 secretion|2008 797 
 
1.74 0.87-3.50 
 secretion|2009 722 
 
2.49 1.33-4.65 
 secretion|2010 841 
 
2.29 1.26-4.17 0.74 
      Mole|total 
 
151029 
   mole|2006 
 
27411 1.27 1.08-1.50 
 mole|2007 
 
31239 1.25 1.07-1.46 
 mole|2008 
 
30937 1.09 0.93-1.27 
 mole|2009 
 
30327 1.18 1.01-1.44 
 mole|2010 
 
31115 1.25 1.09-1.45 0.59 
 
*CI= confidence interval; *no data on radiographer reported secretion; *no data on self-reported mole  
 
Table 4 shows the number of self-reported and radiographer reported symptoms between 2006 and 2010, and the risk of breast 
cancer among screened women. Lump was reported in higher numbers in 2010 by women and the radiographer, 2,070 and 3,225 
cases respectively. The risk of breast cancer in women having lump was 9 fold higher in 2010 and lower in 2007 (6.7 fold). 
Retraction was reported in higher numbers by women in 2009 (959 cases) and by radiographer in 2010 (4,642 cases) whereas the 
risk of breast cancer was higher in 2010 (3.8 fold) and lower in 2008 (1.99 ≈ 2fold). Women having scar was higher in 2009, 
23,554 cases and 30,366 cases by women and radiographer respectively whereas the risk was higher in 2008 (1.41 fold) and was 
almost null in 2007 (1.03). Higher numbers (879 cases) of secretion cases were reported in 2007 but the risk was just 1.35 fold. 
Mole was reported in higher numbers in 2007, 31,239 cases with a risk of 1.25 fold.  
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Table 5: Odds ratios (OR) with confidence intervals (CI) for exposure to self-reported or radiographer reported 
symptoms reported by age at screening visit  
 
     
Symptoms/Agegroup Self-reported 
Radiographer 
reported 
Odds 
ratio 95% CI 
P-value for 
homogeneity 
 
Lump|agegroup 
     lump|50-54 4058 6142 8.93 7.34-10.8 
 lump|55-59 2228 3687 8.99 7.08-11.4 
 lump|60-64 1962 3202 7.80 6.14-9.91 
 lump|65-69 481 811 8.86 5.94-13.2 0.22 
     Retraction|agegroup 
    retraction|50-54 1357 6611 2.92 1.72-4.95 
 retraction|55-59 1282 6223 2.68 1.61-4.47 
 retraction|60-64 1164 5855 3.06 1.96-4.78 
 retraction|65-69 245 1643 4.17 1.95-8.90 0.07 
      Scar|agegroup 
     scar|50-54 31009 42871 1.08 0.91-1.29 
 scar|55-59 29507 39224 1.36 1.16-1.59 
 scar|60-64 30621 40639 1.24 1.08-1.42 
 sacr|65-69 8251 11193 1.48 1.19-1.83 0.01 
      Secretion|agegrp 
     secretion|50-54 2081 
 
1.49 0.86-2.57 
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secretion|55-59 943 
 
1.91 0.99-3.68 
 secretion|60-64 721 
 
2.96 1.74-5.03 
 secretion|65-69 220 
 
3.37 1.58-7.18 0.21 
      Mole|agegroup 
     mole|50-54 
 
52734 1.19 1.05-1.36 
 mole|55-59 
 
42885 1.05 0.91-1.21 
 mole|60-64 
 
42343 1.15 1.02-1.30 
 mole|65-69 
 
13067 1.30 1.09-1.56 0.28 
 
*CI= confidence interval 
 
Table 5 shows the number of self-reported and radiographer reported symptoms in age-group between 50-54 years and 60-69 
years, and the risk of breast cancer among screened women. Lump was reported in higher numbers in age-group 50-54 years by 
women and the radiographer, 4,058 and 6,142 cases respectively and with a risk of 8.93 fold. The risk of breast cancer in women 
having lump was 8.99 (≈9 fold) times higher in age-group 55-59 years and lower in age-group 60-64 years (7.8 fold). Likewise, 
retraction was reported in higher numbers by women  and radiographer in age-group 50-54 years, 1,357 cases and 6,611 cases 
respectively whereas the risk of breast cancer was higher in age-group 65-69 years (4.17 fold) and lower in age-group 55-59 
years (2.68 fold). Similarly, scar was reported higher in age-group 50-54 years, 31,009 cases and 42,871 cases by women and 
radiographer respectively. The risk was higher in age-group 65-69 years (1.48 fold) and almost no additional risk in age-group 
50-54 years (OR=1.08). Secretion cases were reported in higher numbers in age-group 50-54 years, 2,081 cases and a small risk 
of 1.49 fold. Mole was reported in higher numbers in younger age-group (50-54 years), 52734 cases and a small risk of 1.19 fold. 
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Table 6: Odds ratios (OR) with 95% confidence intervals (CI) for joint exposure to self-reported or radiographer 
reported symptoms 
 
Symptoms characteristics 
(self-reported) 
Odds 
ratio CI at 95% 
 
Symptoms characteristics 
(radiographer reported) Odds ratio 95% CI 
 
Sf-lump # sf-retraction 
  
 
Ip-lump # ip-retraction 
  0 0 1 
 
0 0 1 
 0 1 2.45 1.85-3.24 0 1 1.94 1.68-2.24 
1 0 6.95 6.18-7.82 1 0 6.46 5.85-7.14 
1 1 39.6 23.5-66.8 1 1 21.81 15.5-32.7 
 
Sf-lump # sf-scar 
  
Ip-lump # ip-scar 
  0 0 1 
 
0 0 1 
 0 1 1.32 1.22-1.43 0 1 1.29 1.20-1.39 
1 0 7.79 6.89-8.00 1 0 7.21 6.49-8.01 
1 1 5.55 4.03-7.64 1 1 5.89 4.69-7.40 
 
Sf-retraction # sf-scar 
  
Ipretraction # ip-scar 
  0 0 1 
 
0 0 1 
 0 1 1.32 1.22-1.43 0 1 1.29 1.21-1.40 
1 0 3.12 2.43-4.11 1 0 2.18 1.89-2.53 
1 1 3.21 1.71-5.99 1 1 2.35 1.74-3.17 
 
Sf-lump # sf-retraction # sf-
scar 
  
Ip-lump # ip-retraction #ip- 
scar 
  0 00 1 
 
0 00 1 
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0 0 1 1.32 1.21-1.43 0 0 1 1.29 1.19-1.39 
0 1 0  2.46 1.81-3.34 0 1 0  1.95 1.66-2.29 
0 1 1 2.82 1.40-5.68 0 1 1 2.26 1.65-3.10 
1 0 0 7.46 6.58-8.45 1 0 0 6.87 6.16-7.67 
1 0 1 5.42 3.90-7.51 1 0 1 5.79 4.57-7.33 
1 1 0 58.79 33.0-104 1 1 0 26.52 18.3-38.3 
1 11 12.25 2.93-51.1 1 11 11.4 4.63-28.1 
 
*sf= self-reported; ip= inspection palpation (radiographer reported); CI= confidence interval 
*0= absence of symptom; 1= presence of symptom 
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Table 6 shows the breast cancer risk for joint exposure to self-reported or radiographer 
reported symptoms. The combined effect of self-reported lump and retraction showed a 
significant effect in the risk (39.6 fold) of breast cancer compared to those who do not have 
any of the symptoms. The risk of breast cancer among women who reported lump and scar 
was 5.55 times higher compared to those who reported none of the symptoms however 
lump alone had 7.79 fold risks. Women reported retraction and scar were 3.21 times higher 
risk of breast cancer. In three-way interaction women who reported all of the three 
symptoms were 12.25 fold higher risks however those women who reported lump and 
retraction but no scar were 58.79 fold higher risk of breast cancer. 
The combined effect of radiographer reported lump and retraction showed a significant 
21.8 fold increase in the risk of breast cancer compared to those who do not have any of the 
those symptoms. The risk of breast cancer among women who had lump and scar and 
reported by radiographer was 5.89 times higher compared to those who reported none of 
the symptoms however lump alone had 6.46 folds risk. Those women who were reported by 
radiographer as having retraction and scar were 2.35 times higher risk of breast cancer. In 
three-way interaction women who were reported by radiographer as having all of the three 
symptoms were 11.4 fold increased risks however those women reported as having lump 
and retraction but no scar were 26.52 fold increased risk of breast cancer.  
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Table 7: Recall rate among screened women reported as having symptoms, self-reported (sf) and radiographer reported 
(ip)  
   
Recall 
   
  
Cases (%) No cases (%) Total (%) 
Odds 
ratio 95% CI 
Self-reported 
 
     Lump Yes 1333(15.3) 7392(86.7) 8730(0.73) 7.19 6.98-7.64 
 
No  29058(2.4) 1160543(97.6) 1189601(99.3) 1 
Retraction Yes 177(4.37) 3872(95.6) 4049(0.34) 1.76 1.51-2.05 
 
No  30214(2.53) 1164067(97.5) 1194281(99.7) 1 
Scar Yes 2969(2.99) 96426(97.0) 99395(8.29) 1.2 1.16-1.25 
 
No  27422(2.50) 1071515(99.5) 1098937(97.5) 1 
Secretion Yes 310(7.82) 3655(92.2) 3965(0.33) 3.28 2.92-3.69 
 
No  30081(2.52) 1163956(97.5) 1194364(99.7) 1 
     Radiographer 
reported 
    Lump Yes 2028(14.7) 11814(85.4) 13842(1.16) 6.99 6.66-7.34 
 
No  28363(2.39) 1156123(97.6) 11486(98.8) 1 
Retraction Yes 693(3.41) 19639(96.6) 20332(1.70) 1.36 1.26-1.43 
 
No  29698(2.52) 1148298(97.5) 1177996(98.3) 1 
Scar Yes 4009(2.99) 129918(97.0) 133927(11.2) 1.21 1.17-1.25 
 
No 26382(2.48) 1038019(97.5) 1064401(88.8) 1 
Mole Yes 3976(2.63) 147053(97.4) 157029(12.6) 1.04 1.01-1.08 
 
No 26415(2.52) 1020884(97.5) 1047299(87.4) 1 
*CI= confidence interval 
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The above table shows the recall rate in women having symptoms either self-reported or 
radiographer reported. Out of the 8,730 screening visits by women who reported lump 
1,333 (15.3%) cases were recalled whereas only 177 (4.37%) cases who reported retraction 
were recalled. 2,969 (2.99%) scar cases reported by women were recalled whereas 310 
(7.82%) screening cases having secretion were recalled. Women who reported lump had 
7.19 times higher chances of being recalled compared to those who did not report lump 
while retraction had only 1.76 times higher chances of being recalled. Women who 
reported scar had 1.2 times higher chances of being recalled however secretion had 3.28 
times higher chances of being recalled compared to those who did not report symptoms.  
In radiographer reported symptoms, out of the 13,842 screening visits lump 2,028 (14.6%) 
cases were recalled whereas only 693 (3.41%) cases of retraction were recalled. Altogether 
133,927 scar cases were reported by the radiographer out of which 4,009 scar cases 
(2.99%) were reported by women were recalled whereas 3,976 (2.63%) screening cases 
having mole were recalled. Radiographer reported lump had 6.99 (≈7) times higher chances 
of being recalled compared to those without lump while retraction had only 1.36 times 
higher chances of being recalled. Women who reported scar had 1.21 times higher chances 
of being recalled however there was very small difference (OR=1.04) in the chances of 
being recalled for those women who were reported as having mole.   
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Table 8: Referral rate among screened women reported as having symptoms, self-reported (sf) and radiographer 
reported (ip) 
   
Referral 
   
 
 
Cases (%) No cases (%) Total (%) 
Odds 
ratio 95% CI 
Self-reported 
     Lump Yes 388(4.82) 7659(95.2) 8047(0.74) 7.00 6.31-7.78 
 
No 7705(0.72) 1065803(99.3) 1073528(99.3) 1 
Retraction Yes 74(2.19) 3303(97.8) 3377(0.31) 2.99 2.37-3.77 
 
No 8019(0.74) 1070159(99.3) 1078178(99.7) 1 
Scar Yes 909(0.99) 90754(99.0) 91663(8.48) 1.37 1.28-1.47 
 
No 7184(0.73) 982708(99.3) 989892(91.5) 1 
Secretion Yes 87(2.39) 3559(97.6) 3646(0.34) 3.27 2.64-4.04 
 
No 8006(0.74) 1069903(99.3) 1077909(99.7) 1 
Radiographer 
Reported 
    Lump Yes 571(4.38) 12461(95.6) 13032(1.20) 6.46 5.92-7.05 
 
No 7522(0.70) 1061001(99.3) 1068523(98.8) 1 
Retraction Yes 266(1.38) 18975(98.6) 19241(1.78) 1.89 1.67-2.13 
 
No 7827(0.74) 1054487(99.3) 1062314(98.2) 1 
Scar Yes 1181(0.94) 123867(99.1) 125048(11.6) 1.31 1.23-1.39 
 
No 6912(0.72) 949595(99.3) 956507(88.4) 1 
Mole Yes 1169(0.82) 141470(99.2) 142639(13.2) 1.11 1.04-1.18 
 
No 6924(0.74) 931992(99.3) 938916(86.8) 1 
*CI= confidence interval 
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Table 8 shows the referral rate in women either self-reported or radiographer reported 
symptoms. Out of the 8,047 screening visits by women who reported lump 388 (4.82%) 
cases were referred whereas only 74 (2.19%) cases who reported retraction were referred. 
909 (0.99%) scar cases reported by women were referred likewise 87 (2.39%) screening 
cases having secretion were referred. Women who reported lump had 7 times higher 
chances of being referred compared to those who did not report lump while retraction had 
only 2.99 (≈3) times higher chances of being referred. Women who reported scar had 1.37 
times higher chances of being referred however secretion had 3.27 times higher chances of 
being referred compared to those who did not report symptoms.  
In radiographer reported symptoms, 571 (4.38%) lump cases out of the 13,032 were 
referred whereas only 266 (1.38%) cases of retraction were referred. 1,181 (0.94%) of the 
total scar cases reported by the radiographer were referred whereas 1,169 (0.82%) 
screening cases having mole were referred. Radiographer reported lump had 6.46 times 
higher chances of being referred compared to those without lump while retraction had only 
1.89 times higher chances of being referred. Women who reported scar had 1.31 times 
higher chances of being recalled however women who were reported as having mole had 
1.11 times higher chances of being referred.  
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Table 9: Clinical validity of symptoms; sensitivity, specificity and PPV 
 
Lump Retraction Scar Secretion Mole 
True positives 501 243 972 43 963 
True negatives 1176698 1171147 1052622 1187862 1041717 
False positives 15085 20636 139158 3922 150066 
False negatives 6044 6302 5873 6502 5582 
Sensitivity % 
 
7.65 
(7.04-8.32) 
3.71 
(3.28- 4.20) 
14.8 
(14.0-15.7) 
0.66 
(0.49-0.88) 
14.7 
(13.8-15.6) 
 
Specificity % 
 
98.7 
(98.7-98.8) 
98.3 
(98.2-98.4) 
88.3 
(88.3-88.4) 
99.7 
(99.6-99.7) 
87.4 
(87.3-87.5) 
 
Positive predictive 
value 
6.05 
(5.55- 6.59) 
2.14 
(1.89-2.43) 
1.27 
(1.20-1.36) 
1.99 
(1.48-2.69) 
1.17 
(1.10-1.24) 
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The above table shows the clinical validity of the symptoms in terms of sensitivity, 
specificity and positive predictive value. The sensitivity for women who had lump was 
7.65% whereas in case of retraction the sensitivity was 3.71% sensitivity. The sensitivity 
for the women who had scar, secretion and mole was 14.8%, 0.66% and 14.71% 
respectively. Similarly, specificity was 98.7% for women who had lump and 98.3% for 
those with retraction. The specificity for women who had scar, secretion and mole was 
88.3%, 99.7% and 87.41% respectively. The positive predictive value for women who had 
lump was 6.05% and for retraction the value was 2.14%. Those women who had scar, 
secretion and mole the positive predictive value was 1.2%, 1.99% and 1.17% respectively.   
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Table 10: Tumor characteristics of varying size and grades  
 
 
 
Tumor characteristics Numbers (%) 
 
Invasive Size in histology 
 
 
Less than 10 mm 1269(24.6) 
 
10 - 19 mm 2566(49.7) 
 
20 - 49 mm 1201(23.2) 
 
50 - 150 mm 129 (2.50) 
 
Total 5165(100) 
 
Grade 
 
 
Well differentiated 1570(30.0) 
 
Moderately differentiated 2525(48.2) 
 
Poorly differentiated 1143(21.8) 
 
Total 5238(100) 
 
TNM classification 
 
 
pT 
 
 
pT0 1(0.1) 
 
pTx 3(0.3) 
 
pT1 944(98.0) 
 
pT3 15(1.56) 
 
Total 963(100) 
 
pN 
 
 
pN0 3535(68.2) 
 
pN1 1607(31.0) 
 
pN2 40(0.8) 
 
Total 5182(100) 
 
pM 
 
 
pM0  4218(83.9) 
 
pM1 33(0.7) 
 
pMX 773(15.4) 
 
Total 5024(100) 
In-situ Size in histology 
 
 
lessthan 10 mm 227(30.4) 
 
10 - 19 mm 218(29.1) 
 
20 - 49 mm 232(31.0) 
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50 - 150 mm 71 (9.49) 
 
Total 748(100) 
Benign Size in histology 
 
 
Less than 10 mm 36(38.3) 
 
10 - 19 mm 34(36.2) 
 
20 - 49 mm 21(22.3) 
 
50 - 150 mm 3 (3.19) 
 
Total 94(100) 
 
*TNM= TNM Classification of Malignant Tumors; pT= primary tumor; pT0= no evidence 
of primary tumor; pTX= primary tumor cannot be assessed; pT1= tumor 2 cm or less in 
dimension; pT3= tumor more than 5 cm; pN= regional lymph nodes; pN0= no regional 
lymph node metastasis; pN1= metastasis with 1-3 ipsilateral lymph nodes; pN2= metastasis 
with 4-9 ipsilateral lymph nodes; pM= distant metastases; pM0= no distant metastases; 
pMX= distant metastases cannot be assessed; pM1= distant metastases 
 
Table 10 shows the size and grade of tumors in women who had either malignant or non-
malignant outcome. In women with histological confirmed breast cancer, 2,566 (49.7%) 
women were found with the tumor size of 10-19mm whereas 129 (2.5%) of the women had 
tumor size of 50-150mm. 1,570 (30%) women with invasive cancer had well differentiated 
grades whereas 1143 (21.8%) women had poorly differentiated grades. According to 
pTNM classification, 944 (98%) women with invasive cancer had primary tumor size of 
less than 2 cm whereas 15 (1.56%) women had tumor size of more than 5cm. Similarly, 
1,607 (31%) of the invasive cancer tumors had metastasis with 1-3 axillary lymph nodes 
involvement and 40 (0.8%) tumors had metastasis with 4-9 axillary lymph nodes 
involvement. 33 (0.7%) of the invasive cancer tumors had distant metastasis whereas 4,218 
(83.9%) tumors had no distant metastasis. Out of the 748 histological confirmed in-situ 
carcinomas 445 (59.5%) tumors were less than 20 mm whereas 71 (9.49%) of the tumors 
were 50-150mm. Histological confirmed benign tumors were 91 altogether, out of which 70 
(74.5%) were less than 20mm and 3 (3.19) were 50-150mm in size. 
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Table 11: Association of tumor size and breast cancer symptoms with breast cancer, calculating odds ratios (OR) and 
confidence intervals (CI) 
 
 
 
  
Breast cancer 
    Tumorsize in 
histology Cases 
No 
cases 
Odds 
ratio 95% CI 
Symptom|Tumor 
size in histology 
Odds 
ratio 95% CI 
<10 mm 1496 36 0.56 0.37-0.86 <10 mm 3.69 3.29-4.16 
 
10-19 mm 2784 35 1.55 1.02-2.36 10-19 mm 4.14   3.70-4.63 
 
20-150 mm 1633 25 1.08 0.68-1.72 20-150 mm 3.58   3.18-4.03 
 *CI= confidence interval *Symptom= breast lump 
 
The above table shows the breast cancer risk among women with varying tumor size and who had breast lump. Breast cancer risk 
was significantly lower (OR= 0.56) in women who had tumor size of <10 mm compared to bigger tumor size. However, the risk 
increased significantly (OR= 3.69) among women who had lump and had tumor size of <10 mm. Similarly, breast cancer risk 
was 1.55 times higher in women with tumor size of 10-19mm compared to other tumor size. The risk increased even higher 
(OR= 4.14) when calculated among women having breast lump and tumor size of 10-19 mm. Breast cancer risk was 3.58 times 
higher in women who had tumor of 20-150 mm size and who were detected as having lump in the breast.  
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6. DISCUSSION 
 
 
The purpose of the study was to examine the association between the proportion of women 
who were presented with symptomatic findings in the screening visit and later development 
of breast cancer, as well as, the comparison of tumor characteristics between symptomatic 
and asymptomatic women. The large dataset of about 1.2 million screening visits for 
mammography allows the understanding of breast cancer risk at the population level among 
women who had symptoms. The study found the significant association of breast cancer 
symptoms with the occurrence of breast cancer, where breast lump showed the most 
significant association.  
 
This study found the symptoms either self-reported or radiographer in 25% of the screening 
exams. This is higher than the screening reported study on post-menopausal women where 
the prevalence is below 10% (Aiello et al. 2004). The explanation may be that in our study 
more symptoms variables were included and symptoms were considered valid whether 
reported by women or by the radiographer. However, the prevalence is more than 30% in 
studies which reported symptoms through diagnostic mammography exam (Aiello et al. 
2004; Barlow et al. 2002; Geller et al. 2002). The reasons for higher prevalence of 
symptoms in diagnostic mammographic exam may be that only selective women visit to 
have mammography and those studies included younger women than our study and hence, 
the prevalence of breast symptoms was found higher (Morrow 2000). Barton and his 
colleagues found a 16% prevalence of breast symptoms among 2400 women who had 
diagnostic mammography exams (Barton & Elmore 1999), which is lower than the rate 
found in our study. That study was only based on the physical examination findings by the 
physician but in our study both self-reported and radiographer reported findings were 
analyzed.  
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Our finding on the overall rate of breast cancer diagnosed among women having any 
symptoms was 0.78% which is quite low compared to other studies. Aiello and his 
colleagues reported that 6.6% of women with symptoms at diagnostic examination and 
1.3% of women at screening examination were diagnosed with breast cancer (Aiello et al. 
2004). Williams et al. also found the breast cancer rate of 9% which is higher than the 
findings of our study (Williams et al. 2002). However, they evaluated only those women 
with ‘significant’ breast symptoms as defined by Breast Test Wales (BSW) guidelines. 
Williams noted that BSW guidelines for ‘significant’ symptoms includes new lump, 
persistent localized pain, recent unilateral nipple retraction, recent unilateral nipple 
discharge, skin dimpling, raw nipple. The Seltzer (1992) study reported even higher rate 
(16%) of breast cancer diagnosed among women with symptoms or prior abnormal 
mammography that were referred for diagnostic examination. One reason may be that our 
study was done among general population (women) most of who comes for screening in a 
regular basis (once in every two years) under nationwide organized screening program. 
Moreover, in our study self-reported symptoms was solely categorized within the past 2 
months prior to the screening and radiographer reported only those symptoms which was 
detected at the time of the respective screening visit. 
 
Likewise, in our study breast cancer rate among women with any of the given symptoms 
was 0.66% in age-group 50-59 years and 0.99% in age-group 60-69 years. Tests for trend 
with age showed a significant (p-value <0.05) increase in the breast cancer risk among 
women who have any of the symptoms. Sterns’ (1992) study in symptomatic patients found 
the cancer rate was significantly age-related, being 0.8% in women younger than 40 years 
and 5% in those between 41 and 55 years. Kerin et al. (1997) evaluated the symptomatic 
breast disease in 585 patients without clinical evidence, found breast cancer rate of 2.2% in 
patient age-group 40-49 years, 4.5% in patient aged 50-59 years and 3.1% in patient >60 
years of age. In our study number of women with symptoms as well as the number of breast 
cancer cases increased with year between 2006 and 2010. Women reported as having lump 
had a significant increase in risk each year compared to other symptoms. The p-value test 
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for homogeneity showed no heterogeneity (p-value ≥0.05) in the breast cancer risk with the 
increase in age and year of screening among women with symptoms. 
 
This study found the cancer rate of 7.7%, 3.7% and 14.8% in patient with breast lump, 
retraction and scar respectively which is little lower than the study by Lumachi et al. The 
study found cancer rate of 3.2%, 16.4% and 12.0% respectively in patient with breast pain, 
lump and nipple discharge (Lumachi et al. 2002).  In another study by Sterns (1992), breast 
cancer rate was 37%, 11% and 3% in patients with breast mass, nipple discharge and lump 
respectively. The reason for higher rate in these studies is that both studies were done 
among symptomatic patients who are already selective women and have more chances of 
developing cancer but in our study women had screening on a regular basis at the 
population level.  
 
The risk of breast cancer was found to be significantly associated with the occurrence of 
breast cancer. In this study the risk of developing breast cancer was 7-fold and more than 6-
fold in women with self-reported and radiographer reported lump respectively. When using 
interaction effect in the logistic regression model the combined risk was more than 8-fold in 
women with lump. Aiello et al. (2004) reported a risk of more than 3-fold in women who 
had screening exam and about 3-fold risk in diagnostic exam but no significant association 
between nipple discharge, breast pain and breast cancer risk. Similarly, our study evaluated 
a combined risk of 3-fold increase in women who had retraction in their breast and a small 
increase in breast cancer risk in women who had scar. However, we are unaware of other 
epidemiological studies that examined the association between retraction, scar and the 
breast cancer risk. When we did a three-way interaction of symptoms and evaluated risk of 
breast cancer it showed a 12-fold risk in women with self-reported symptoms and 11-fold 
risk in women with radiographer reported symptoms. The higher risk of breast cancer risk 
in our study may be that the information about breast symptoms was systematically 
collected from both women and the radiographer, and also because of the large study 
population. In other hand, the risk estimate in our study is based on those women who had 
screening thus may be confined to self-selection bias as the risk is lower than the average 
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risk in the general population who had no screening. A study by Sarkeala et al. (2008) in 
Finland found 1.56 (95% CI= 1.25-1.91) times higher death rate in women who had no 
screening visits. The interval cancers, since screening visits are made once in every two 
years, can be more aggressive than screen-detected cancers. Hence, the risk might be even 
higher in women who had symptoms and are not screened.   
 
The recall rate (2.54%) in our study was within the range of that found by Sarkeala et al. in 
a study in Finland which ranges between 1% and 3.6% (Sarkeala et al. 2004). Women who 
reported lump were 7-fold higher chances of being recalled compared to retraction and 
secretion which had about 2-fold and more than 3-fold higher chances of being recalled 
respectively. Similar result was found with radiographer reported symptoms. Similarly, in 
this study almost all (99.9%) of the women who referred were diagnosed with cancer. The 
self-reported (or radiographer reported) lump had 7-fold higher chances of being referred 
and women who reported retraction were 3-fold higher chances of being referred. However, 
we have not found other epidemiological studies which evaluated the relation between self-
reported and radiographer reported symptoms with the recall and referral rates.  
 
Sensitivity was quite lower in our study compared to the other studies (Harvey et al. 2003; 
Karla et al. 1996; Bobo et al. 1999) but higher (35.49%) than that reported in a community 
based study among asymptomatic women in USA which reported sensitivity between 
18.1% and 21.6% (Fenton et al. 2005). Findings from a randomized control trial of breast 
cancer screening by CBE in India showed a moderate sensitivity of 51.7% 
(Sankaranarayanan et al. 2011). In our study sensitivity for women who had lump was 
7.65% while specificity was 98.7% and 6.05% PPV. The reason for the lower value of 
sensitivity in our study is mentioned above described as study population. The low 
sensitivity may be explained by the population having lot of diagnostic activities, several 
screens in the programme already before the index screen, as well as access to 
mammograms outside the programme. Therefore, the study population and size to tumors 
in detection may not be similar than in the Sankaranarayanan study. There was a significant 
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difference in the invasive cancer tumor size of less 20mm in diameter, 74.3% versus 18.8% 
in our study and the study by Sankaranarayanan respectively.  
 
Another purpose of our study was to assess the tumor characteristics of various size and 
grades as well as assessing the relation with breast cancer symptoms. 74% of the invasive 
tumors were less than 20mm in diameter whereas only 2.5% of tumors were more than 
50mm and 21.8% of the tumors were poorly differentiated. According to TNM 
classification of tumors, 31% of invasive cancer tumors had 1-3 axillary lymph node 
involvement whereas 0.8% of the invasive tumors had metastasis with 4-9 axillary lymph 
node involvement and only 0.7% of the tumors had distant metastasis. This higher 
proportion of invasive tumors of lesser size and grade shows the early stage diagnosis of 
the disease and highlights the importance of the organized screening program. Similarly, 
other studies have found quite significant difference in tumors characteristics between 
screening detected and symptomatic breast cancer cases (Chuwa et al. 2009; Gibbs 1985;  
Redondo et al. 2012; Allgood et al. 2011; Bucchi et al. 2005; Rajakariar & Walker 1995; 
Dawson et al. 2009; Kim et al. 2012; Joensuu et al. 2004; Ota et al. 1989; Molino et al. 
2000). Breast cancer risk was significantly higher in women who had lump and tumor both 
(OR= 3.69, 4.14 and 3.58 for tumor of <10mm, 10-19mm and 20-150mm respectively). 
However, no other studies have reported such relation between tumor characteristics and 
breast cancer symptoms.  
 
 
6.1. Significance of the study 
 
The study findings showed that presence of lump was associated with 7-fold increase in the 
risk of breast cancer among self-reported and radiographer reported symptoms. In addition, 
when using the interaction effect into the logistic regression model the combined breast 
cancer risk among women reported lump, retraction and scar was 12-fold. Moreover, 35.5% 
of the women who were detected with breast cancer were reported with any of the 
symptoms. Our findings reinforce the importance of the importance of fully evaluating the 
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breast cancer symptoms as a predictor of breast cancer and warrant extra consideration 
when evaluating mammograms of women with symptoms. Also, continual maintaining of 
the information about symptoms at screening visits is useful for clinician as well as for 
epidemiological research.  
 
Although our study was quite new and the results showed higher strength of association 
between symptoms and breast cancer, there might have some weaknesses in the recording 
of the symptoms information in the screening centers. It was not possible to check the 
individual record of all the screening centers. However, based on the quality control checks 
in the data, the centers had very similar rates, suggesting that major differences were not 
there in their practice. Moreover, in Finland overall the tumor size is smaller which might 
be the reason for relatively low sensitivity of the study. Since there were more women with 
symptoms but less breast cancer cases, this might be the reason for lower specificity in our 
study.  
 
 
6.2. Limitations of the study 
 
This study is only limited to those women who came for the screening thus mammography 
outside of the screening is not included. Moreover, breast cancer cases detected outside of 
the screening clinics are excluded. Since only those cancers cases which are detected by the 
screening program between 2006 and 2010 are included thus, screened women who 
developed cancer after 2010 were not followed-up.  
 
This study was limited to only those women who were detected as current cancer cases, and 
women with symptoms were not followed-up thus, the interval cancer rates among women 
with breast symptoms is unknown. Moreover, the shorter study duration limits the 
assessment of cumulative risk of breast cancer in women with subsequent screening rounds 
with or without symptoms of breast cancer. Hence, further study with periodic follow-up of 
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the cases (with sufficient year) could explain more about symptoms and the outcome of 
breast cancer.  
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7. CONCLUSION 
 
 
This is the largest and single study done so far on breast cancer symptoms, either self-
reported or radiographer reported, and breast cancer risk. The fact that all eligible women 
of targeted age-group (aged between 50 and 69 years) of population based national breast 
cancer screening program of Finland were enrolled which is the major strength of the study. 
We were able to collect information on self-reported and radiographer reported symptoms 
and evaluated the risk of breast cancer. In addition, all the malignant breast cancer cases in 
our study were recalled (100%) and referred (99.9%) before diagnosed with cancer which is 
another major strength of our study.  Our study finding may be relevant for a large number 
of countries, especially the developing world (including more symptoms variables) as an 
alternative option in population-based breast cancer control where the mammography 
screening services is not available at the population level.  
 
Taking into account the low sensitivity for symptoms in Finland in diagnosing screen 
detected breast cancer, it is likely that prevention program based on clinical examination 
also would not provide sufficient benefit to cancer control program as that provided by 
mammography screening program. In low resource countries, considering the limited 
resources and services, use of clinical breast examination together with the availability of 
diagnostic services could make an impact at least for detecting large size tumors. However, 
we cannot say about the impact of this study because of the different study settings, age at 
screening, size of the tumors detected, which might be quite different in low resource 
setting with no breast cancer screening services.  
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